Anti-oncolytic virus antigen antibodies and methods of use thereof

Antibodies that specifically bind to a vaccinia virus (VV) A56 or B5 antigen are provided. Fusion proteins and conjugates comprising the antibodies are also provided. Pharmaceutical compositions and kits comprising the antibodies, fusion proteins and conjugates are also provided. Aspects of the disclosure further include methods of using the antibodies, fusion proteins, and conjugates, for example, for therapeutic purposes. In certain embodiments, methods are provided comprising administering to an individual having cancer an antibody, fusion protein or conjugate of the present disclosure wherein the individual comprises cancer cells infected with VV, such as cancer cells infected with VV. And wherein the antibody, fusion protein or conjugate is targeted to a VV antigen infected cancer cell expressed on the surface of the infected cancer cell. Aspects of the disclosure further include methods of targeting an antibody, fusion protein or conjugate that specifically binds to an oncolytic virus (OV) antigen to ca